The overwhelming majority of patient accrual to City of Hope (COH)-sponsored trials without other sources of peer-reviewed support was to Phase l/ll and pilot trials by COM clinical investigators. This was made possible by the protocol specific research support (PSRS) of the CCSG. This resource has played an important role in providing preliminary data for new R01 and P01 proposals. These protocols all are subject to review by the Clinical Protocol Review and Monitoring Committee (CPRMC), as described under the PRMS section. Funding for the PSRS staff will provide the Cancer Center with a stable core of expert staff who are highly qualified to support the conduct and completion of innovative, short-term feasibility studies originating from COHCCC Programs. The studies supported by PSRS are the foundation of the programs in Hematologic Malignancies, Developmental Cancer Therapeutics and Cancer Immunotherapeutics. More than 500 patients per year were accrued to therapeutic clinical trials by these three programs over the last grant cycle;in FY 2006 this accrual grew to 652 patients enrolled on therapeutic trials. Accrual to investigator-initiated, COH-sponsored trials (without other peer-reviewed sources of support) comprised 34% of the patient volume enrolled onto interventional trials in FY 2006. The prioritization of the usage of the resources provided by PSRS (and the oversight of the budget) is performed initially within the clinical research programs themselves and then by the review provided by the Clinical Research Governance Board, chaired by Dr. Robert Figlin. Oversight of the CRAs involved in these trials occurs at several levels including that provided by the clinical research program leaders, the protocol Principal Investigators, and by the Clinical Protocol Management Core (CPMC) training and quality assurance process. All of the CRAs requested in support of protocol specific research from the CCSG are part of the larger, centralized pool of CRAs overseen and administered by the CPMC. Funding is requested to support three full-time equivalents (FTEs) spread over 6 CRAs to cover the broad spectrum of trials and programs, while allowing diseasespecific focus for protocol management of funded trials as well. These CRAs are responsible for protocol monitoring, data collection and data quality control for our in-house Phase I and pilot studies. They help ensure the success of the clinical studies by providing eligibility checks of patients prior to enrollment, assisting in meeting accrual goals, providing follow-up and recording accurate complete subject data.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications